Blog
Long reads, slow takes.
Plain-language writing on peptides and how to read the research around them. Educational, not medical advice.
lifestyle· July 17, 2026
The case for subtraction
Most wellness advice adds one more thing. The more useful move is usually to take something away. On pruning a routine down to what actually earns its place.
explainer· July 15, 2026
What DSIP actually is, and the gap between its name and its evidence
DSIP is sold as a sleep peptide, and the name says so outright. A plain look at where it came from, what the human trials found, and why a molecule named for deep sleep has such a mixed record at producing it.
explainer· July 13, 2026
What Epitalon actually is, and why one replication matters
Epitalon is the longevity peptide with the biggest mythology and one of the thinnest evidence files. A look at where it came from, what a 2025 independent study did and didn't show, and why longer telomeres are not a simple win.
explainer· July 11, 2026
What SS-31 actually is, and the one thing it's approved for
SS-31, or elamipretide, is the first mitochondria-targeted peptide the FDA has approved. A plain look at what it does inside the cell, the narrow condition it's cleared for, and why the trials that aimed wider mostly came up short.
research· July 9, 2026
A mitochondrial peptide got approved. Read what it's approved for.
Elamipretide, the molecule longevity circles know as SS-31, cleared the FDA in late 2025. It's the first cardiolipin-directed mitochondrial therapeutic to reach market, and the details of the approval say more than the headline does.
research· July 7, 2026
The peptide craze meets a hard question
A June Nature feature asked whether the peptide boom is backed by science. The answer, from one of the field's founders, was careful in a way worth borrowing.
lifestyle· July 5, 2026
The results you can't feel
Most of the things worth doing for the long game give you no daily sensation of working. A look at why the missing feedback loop is what quietly ends most routines, and what to anchor to instead.
lifestyle· July 3, 2026
Built for the bad day
Most routines are designed for the version of you who slept well and has time. The one that lasts is the one that still works on the worst day of the month. A case for building to the floor, not the ceiling.
research· July 1, 2026
Retatrutide's first big trial, and the tradeoff hiding in the number
The triple agonist retatrutide posted its first pivotal Phase 3 result. A look at what TRIUMPH-1 actually measured, why the top-line figure is only half the story, and what the trial leaves unanswered.
explainer· June 29, 2026
What TB-500 actually is, and the gap between the fragment and the research
TB-500 is the recovery half of the so-called Wolverine stack. A plain look at what it is, how it differs from the thymosin-β4 molecule it's named after, and where the human evidence runs out.
research· June 27, 2026
The new GLP-1 pills, and why most of them aren't peptides
A wave of oral GLP-1 drugs reported strong phase 2 data at this year's diabetes meeting. The quiet detail worth noticing: the field's most famous peptide is being re-engineered into something that isn't one.
explainer· June 25, 2026
What a biological age test actually measures
Mail-in kits now promise to tell you how old your body really is. A plain look at what those numbers are reading, why two clocks can disagree about the same person, and how much weight a single result deserves.
research· June 23, 2026
Semaglutide and the aging clocks: a small, careful result
A placebo-controlled trial found semaglutide slowed several epigenetic measures of aging. What the clocks actually track, what the result says, and the line the researchers refused to cross.
lifestyle· June 21, 2026
One thing at a time
The instinct in wellness is to stack: add the serum, the supplement, the new habit, all at once. A quieter case for changing one thing and waiting long enough to actually know what it did.
lifestyle· June 19, 2026
The off-season nobody schedules
Serious athletes plan their rest as carefully as their training. Most of us treat recovery as whatever's left over. A case for building the rhythm in on purpose.
explainer· June 17, 2026
What copper peptides actually are, and what the skin studies show
Copper peptides are a fixture of the serum aisle. A plain look at what GHK-Cu is, why it occurs in your own blood, and how to read the cosmetic evidence without rounding up.
research· June 15, 2026
The biggest collagen review yet, and the line it won't cross
Researchers pooled 16 reviews and 113 trials into the largest evidence synthesis on collagen to date. A look at what it found for skin, joints, and muscle, and where it stops short.
research· June 13, 2026
The rules are loosening. The evidence isn't.
The FDA is reviewing whether several popular peptides can move back toward licensed compounding. A plain look at what that process decides, what it doesn't, and why wider access is not the same as stronger proof.
lifestyle· June 11, 2026
Both ends of the sleep curve
A large UK Biobank analysis points to a narrow window where sleep tracks with slower organ aging. The interesting part isn't the floor. It's that there's a ceiling too.
lifestyle· June 9, 2026
The clock you can't see, and the light that sets it
The sun is in our name, so here is an honest look at the role light plays beyond skin: it's the main signal the body uses to keep time. What the research describes, and how a calmer relationship with morning light fits the long game.
explainer· June 7, 2026
What BPC-157 actually is, and what the evidence isn't
BPC-157 is everywhere in recovery circles. A plain look at what the peptide is, what the animal research suggests, and why a 2025 review still calls it investigational.
explainer· June 5, 2026
BPC-157 and the distance between a forum and a trial
BPC-157 is one of the most talked-about peptides online and one of the least studied in people. A plain look at what it is, where its evidence actually comes from, and why the regulators stepped in.
research· June 3, 2026
The muscle question hiding inside the GLP-1 boom
A new mouse study takes aim at lean-mass loss during rapid weight loss. A look at what the result shows, what it doesn't, and why the question matters for aging well.
explainer· June 2, 2026
What people mean when they say "collagen peptides"
The word peptide gets stretched across very different products. A plain-English look at what collagen peptides are, how the oral kind is absorbed, and how to read the evidence.
lifestyle· June 1, 2026
The long game
Why we build for decades instead of weeks, and what a slower approach to skin, recovery, and energy actually looks like day to day.
research· May 30, 2026
How to read peptide research without fooling yourself
A practical, non-technical guide to evaluating early-stage research claims so you can tell a strong finding from a hopeful headline.